Pricing Log in Create free account

Kalaris Therapeutics Inc. (KLRS) vs Serina Therapeutics, Inc. (SER)

Kalaris Therapeutics Inc. and Serina Therapeutics, Inc. are both Biotechnology companies. Kalaris Therapeutics Inc. and Serina Therapeutics, Inc. are of similar size ($47.8M and $45.5M). Across the 10 metrics below, Kalaris Therapeutics Inc. leads on 7 and Serina Therapeutics, Inc. on 3.

Valuation

Metric KLRS SER Biotechnology median
P/E n/m n/m 8.50
P/S n/m 160.23 9.71
P/B 0.83 1.55 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.55 n/m 0.64
EV/Sales n/m 66.04 9.21
Earnings yield (101.00%) (106.78%) (33.15%)
Free cash flow yield (85.89%) (73.10%) (25.50%)

Profitability

Metric KLRS SER Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (79.91%) (306.22%) (56.36%)
Return on assets (46.02%) (136.00%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric KLRS SER Biotechnology median
Revenue growth (TTM) — (94.21%) 6.02%
EPS growth (last fiscal year) 94.50% (26.49%) 30.26%
Revenue growth, 5-year CAGR — (18.48%) 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric KLRS SER Biotechnology median
Debt to equity 0.00 0.16 0.00
Current ratio 10.98 6.65 4.72
Net debt to EBITDA 2.54 0.00 0.96

Dividend

Metric KLRS SER Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric KLRS SER Biotechnology median
Market cap 47.83m 45.46m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack